Long-term use of first-line highly active antiretroviral therapy is not associated with carotid artery stiffness in human immunodeficiency virus-positive patients  by Zhu, Haohui et al.
b r a z j i n f e c t d i s . 2 0 1 4;1  8(5):496–500
The Brazilian Journal of
INFECTIOUS  DISEASES
www.elsev ier .com/ locate /b j id
Original article
Long-term  use  of  ﬁrst-line  highly  active
antiretroviral therapy  is  not associated  with carotid
artery stiffness  in human  immunodeﬁciency
virus-positive patients
Haohui Zhua,b, Jianjun Yuanb, Yisa Wangb, Fan Gaob, Xiao Wangb, Changhua Weib,
Jiyun Chenb, Xiaohui Fanb, Mei Zhanga,∗
a Department of Cardiovascular, Qilu Hospital, Shandong University, Jinan, China
b Deparment of Ultrasound, Renmin Hospital, Zhengzhou University, Zhengzhou, China
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 25 November 2013
Accepted  28 February 2014
Available online 10 May 2014
Keywords:
Artery stiffness
AIDS
Ultrasound
HAART
a  b  s  t  r  a  c  t
Objective: To evaluate whether or not highly active antiretroviral therapy is associated
with  carotid artery stiffness in human immunodeﬁciency virus-positive patients in Henan
Province,  China.
Method:  Fifty human immunodeﬁciency virus-positive patients with at least a 5-year history
of highly active antiretroviral therapy use and 50 human immunodeﬁciency virus-positive
patients  without a history of highly active antiretroviral therapy use were enrolled in this
study.  Carotid artery intima-media thickness and stiffness were determined by quantitative
inter-media  thickness and quantitative artery stiffness, respectively.
Results:  No statistically signiﬁcant difference in carotid artery intima-media thickness and
stiffness  was observed between groups. A signiﬁcant association between human immuno-
deﬁciency  virus infection time and carotid artery stiffness was observed, but no signiﬁcant
association  between human immunodeﬁciency virus infection time and intima-media
thickness  was found. No signiﬁcant association between intima-media thickness, stiffness,
and  CD4+ and CD8+ T-cell counts were observed.
Conclusion: The ﬁrst-line highly active antiretroviral therapy currently used in China is not
associated with carotid artery stiffness in human immunodeﬁciency virus-positive patientswith good highly active antiretroviral therapy compliance. Human immunodeﬁciency virus
may play a role in the development of atherosclerosis.
© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND∗ Corresponding author.
E-mail  address: meizhangcn@126.com (M. Zhang).
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ntroduction
ighly active antiretroviral therapy (HAART) has beneﬁted
uman  immunodeﬁciency virus (HIV)-infected patients since
996.  Mounting evidence shows that HAART helps controlling
IV  replication and lead to a remarkable reduction in mortal-
ty  rates.1 However, as HAART has become more  widely used,
eports  of increased risks of cardiovascular diseases of those
n  HAART have emerged.2–4 Some researchers have focused
n  subclinical atherosclerosis,5–8 and endothelial functions,
arotid intima-media thickness (IMT), artery distensibility
oefﬁcient, and pulse wave  velocity (PWV) have been used to
ssess artery stiffness in HIV-infected patients.9–12 However,
hether HAART leads to artery stiffness remains unclear, and
tudies  on the association between carotid artery stiffness and
AART,  especially in China, are limited. The present research
ims  to study whether ﬁrst-line HAART is associated with
arotid  artery stiffness in HIV-positive patients from Henan
rovince,  China.
ubjects  and  methods
tudy  population
his was  a cross-sectional study conducted from April 2013 to
uly 2013. All participants were  recruited from the countryside
f  Henan Province, China and infected with HIV by blood trans-
usion.  Participants were followed since ﬁrst diagnosed with
IV  infection and had over 10 years of HIV infection history.
All  participants were approached by the interviewers dur-
ng  routine medical examination. Inclusion criteria were as
ollows:  age between 18 and 60 years; normal body mass index
BMI);  no family history of coronary artery disease, hyperten-
ion,  or diabetes; and no history of cardiovascular disease,
yperlipidemia, or other disease, such as heart or kidney
ailure,  and tumors. HIV patients received HARRT (D4T or
ZT  + 3TC or DDI + NVP or EFV) for over ﬁve years with treat-
ent  compliance above 80%. Compliance was  evaluated by
harmacy  supply of antiretroviral drugs every month. Opera-
ionally,  treatment compliance was  calculated as number of
ays  without antiretrovirals in the period/number of days in
he period. Individuals with active infection as well as those
ho  received other medications that could affect artery stiff-
ess  for over three months during the past six months were
xcluded  from the study. Smokers, alcoholics, and pregnant
omen  were  also excluded. All participants had normoten-
ion,  ortholiposis, euglycemia, and normal BMI. Fasting blood
lucose  levels within 3.89–6.11 mmol/L, triglycerides less than
.70  mmol/L, and total cholesterol less than 5.18 mmol/L was
onsidered  normal, according to Chinese adult dyslipidemia
revention guide (2007). BMI  within 18.5–22.9 kg/m2 was con-
idered  normal according to the diagnostic criteria of BMI  by
HO  for Asian-Paciﬁc region. Normal blood pressure (BP) was
eﬁned  as two measurements at different times wherein a
ystolic  BP of no more  than 140 mmHg  and a diastolic BP of
o  more  than 90 mmHg, according to the diagnostic criteria of
ypertension  detection in the seventh report of USA assess-
ent  and treatment of hypertension prevention detection of4;1 8(5):496–500  497
the Joint National Committee (JNC 7). Carotid artery IMT  less
than  1.0 mm and absence of atherosclerotic plaques were con-
sidered  normal, according to the ultrasound examination and
diagnostic  criteria of Atherosclerotic stenosis in the ultra-
sound  conference of Radiological Society of USA (October
2002).
Electrocardiogram showed a normal sinus rhythm without
any  remarkable abnormality, such as myocardial ischemia or
myocardial infarction. Chest X-ray showed no serious ﬁndings,
such  as pulmonary hypertension, pneumonia, or tumor. Ultra-
sound  examination showed no severe heart, liver, spleen, or
kidney diseases, such as heart failure, myocardiopathy, severe
valvular  disease, or tumors. Carotid artery ultrasound showed
no  intima-media thickening, atherosclerotic plaque, or other
arterial  diseases (e.g., Takayasu arteritis and aneurysm). This
study  was  conducted in accordance with the declaration of
Helsinki  and approved by the Ethics Committee of People’s
Hospital of Zhengzhou University. Written informed consent
was  obtained from all participants.
Data  collection
Fifty HIV-infected patients who received ﬁrst-line HARRT com-
prised the therapy group. Patients (males, 52%; females, 48%)
received  ﬁrst-line HAART from 5 to 13 years (mean, 9.07 ± 2.16
years).  Another 50 HIV-infected patients (males, 50%; females,
50%)  who were not on HARRT comprised the non-therapy
group. Gender and age were similar between the two groups.
In  the morning after a 12-h fast, venous blood was  sampled
and  tested for glucose, triglycerides, total cholesterol (via the
enzymatic  method; Olympus AU5400, Japan), and CD4+ and
CD8+ T-cell counts (via cytometry; FacsCalibur (three colors),
Becton  Dickinson, USA). Patient height, weight, and BP were
measured,  and BMIs were calculated.
Carotid artery stiffness was  determined by an Esaote
MyLab90 ultrasound system (Esaote Company, Italy) with
quantitative inter-media thickness (QIMT) and quantitative
artery stiffness (QAS) software using a 5–13 MHz probe. Par-
ticipants  were asked to lie down in a horizontal position for
10  min, after which their BP was  measured and entered into
the  computer system. The acoustic beam was  placed verti-
cally  to the right carotid artery wall to obtain clear imaging
of  the three layers of the anterior and posterior artery walls.
QIMT  was used to determine the IMT of the right carotid
artery. The ROI of QIMT was  placed 1.0 mm below the carotid
sinus,  and the diameter and IMT of the carotid artery were
automatically obtained for six continuous cardiac circles. The
images  were  frozen and the data were recorded by the system
(Fig.  1). QAS was  used to obtain the stiffness parameters of the
carotid  artery, including compliance coefﬁcient (CC), stiffness,
and  PWV  with the similar method (Fig. 2). All carotid artery
ultrasound examinations were performed by an experienced
sonographer.
Statistically  analysisSPSS 15.0 was used to analyze the data. Continuous vari-
ables  are described as mean ± SD, while categorical variables
are  described as percentages. IMT and stiffness parameters
were  compared between therapy and non-therapy groups.
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Fig. 1 – Imaging of QIM in HIV-infected patients on HAART.
DiscussionFig. 2 – Imaging of QAS in HIV-infected patients on HAART.
Parameters with normal distribution were compared by
parametric  tests, such as student t-test. In case of non-
normal  distribution, non-parametric statistical tests such as
Student–Newman–Keuls and Kruskal–Wallis tests were  used.
The  associations between carotid artery IMT, stiffness, CD4+
and CD8+ T-cell counts, and HIV infection time were  also
Table 1 – Characteristics of the study population.
Th
Age (years) 4
Males 5
BMI (kg/m2) 2
Systolic blood pressure (mmHg) 12
Diastolic blood pressure (mmHg) 7
Triglycerides (mmol/L) 
Total cholesterol (mmol/L) 
Glucose (mmol/L) 
Time of HIV infection history (years) 1
CD4+ 41
CD8+ 98
There were no statistically signiﬁcant difference of baseline characteristic
BMI, body mass index; CD4+, CD4+ T-cell count; CD8+, CD8+ T-cell count. 1 4;1  8(5):496–500
analyzed using linear regression models, and correlations
were assessed using Pearson correlation coefﬁcients. Statis-
tical  signiﬁcance was  deﬁned as p < 0.05.
Results
Characteristics  of  the  study  population
The study enrolled 100 individuals, including 50 HIV-infected
patients who received ﬁrst-line HAART and 50 HIV-infected
patients who were  not on HAART. The two groups were
matched by age and gender. No statistically signiﬁcant differ-
ence  was  observed between groups in terms of mean values
of  BMI, systolic BP, diastolic BP, triglycerides, total cholesterol,
glucose, years of HIV infection, and CD4+ and CD8+ counts
(p  > 0.05). The characteristics of the subjects are shown in
Table  1.
Carotid  artery  IMT  and  stiffness  of  the  study  population
No statistically signiﬁcant difference in mean values of IMT,
CC,  stiffness, and PWV  were  observed between the therapy
and  non-therapy groups (p > 0.05). The carotid artery stiffness
was  similar between groups, and relevant values are shown in
Table  2.
Correlations  between  carotid  artery  IMT,  stiffness,  HIV
infection  time,  and  CD4+ and  CD8+ T-cell  counts
Negative correlations between HIV infection time and CC as
well  as positive correlations between HIV infection time and
stiffness  and PWV  were  observed. Carotid artery IMT  was  not
correlated  with HIV infection time, and no statistically sig-
niﬁcant  association between carotid artery IMT,  stiffness, and
CD4+ and CD8+ T cell counts was  found (p > 0.05). The Pearson
coefﬁcients and p-values are shown in Table 3.This study compared HIV-infected patients on long-term
HAART (over 5 years) as a ﬁrst-line treatment to naïve
erapy group Untreated group
9.43 ± 5.42 48.03 ± 7.81
2% (26) 50% (25)
1.57 ± 1.99 21.22 ± 1.97
4.32 ± 10.25 123.45 ± 8.58
8.57 ± 7.62 78.69 ± 7.92
1.41 ± 0.34 1.41 ± 0.32
4.64 ± 0.59 4.54 ± 0.74
5.58 ± 0.57 5.41 ± 0.69
4.68 ± 3.70 14.93 ± 3.82
3.07 ± 163.610 443.62 ± 213.647
4.64 ± 515.033 1059.66 ± 486.149
s between therapy and untreated groups.
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Table 2 – Carotid artery IMT  and stiffness between
HAART experienced (therapy group) and naïve
(untreated group) HIV-infected patients.
Therapy group Untreated group p value
IMT (m) 577.11  ± 120.99 569.00  ± 94.63 0.770
CC (mm2/kPa) 0.6036 ± 0.2256 0.5907 ± 0.2094 0.865
ˇ 13.6521 ± 7.0051 13.0069 ± 6.1013 0.672
PWV (m/s) 8.99 ± 2.56 8.704 ± 1.65 0.582
There was no statistically signiﬁcant difference of carotid artery
IMT and stiffness between therapy group and untreated group.
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HIMT, intima-media thickness; CC, compliance coefﬁcient; ˇ, artery
stiffness; PWV, pulse wave velocity.
IV-infected patients. All patients came from the country-
ide  of Henan Province, China. The usual ﬁrst-line treatment
or  AIDS in China is D4T or AZT + 3TC or DDI + NVP or
FV,  which includes two nucleoside reverse transcriptase
nhibitors (NRTIs) and one non-nucleoside reverse transcrip-
ase  inhibitor (NNRTI). In this study, we  excluded traditional
isk  factors for atherosclerosis, including diabetes melli-
us,  hyperlipidemia, hypertension, fat, and smoking. Carotid
rtery  IMTs were  similar between HAART experienced and
aïve  patients, which is consistent with the study by Cur-
ier  et al.13 Other researchers, however, showed different
ndings. Lorenz et al.14 demonstrated that HIV and HAART
hicken carotid artery IMTs and are independent factors for
eveloping  atherosclerosis. Ross et al.11 found that myeloper-
xidase, soluble vascular cell adhesion molecule-1, and tumor
ecrosis  factor-, all of which could induce cardiovascular
isease, are correlated with IMT  in HIV-infected patients on
AART.  Johnsen et al.15 showed that protease inhibitor (PI)
ould  induce IMT  thickening. However, in the present work, PI,
hich has a side-effect of inducing fat metabolism disorders
as  not studied.
Carotid artery stiffness was  similar between the HAART
xperienced and naïve groups. Thus, long-term HAART is
ot  associated with atherosclerosis. Several reasons may
xplain  these ﬁndings: ﬁrst, NRTIs and NNRTIs are seldom
eported to induce side-effects that lead to metabolic-related
actors of atherosclerosis, such as hyperglycemia, insulin
esistance, dyslipidemia, and fat redistribution. Second, con-
istent  HAART use may  improve immunological functions of
IV-infected  patients and thus outweigh its adverse metabolic
ffects.16 Third, previous reports show that inconsistent
AART use may  be correlated with atherosclerosis.17,18 In the
Table 3 – The association of CD4+, CD8+ T-cell count and carotid
IMT CC 
HIV 0.191/0.090 −0.575/0.000a
CD4+ 0.000/0.995 0.093/0.494 
CD8+ 0.012/0.931 −0.097/0.474 
IMT, intima-media thickness; CC, compliance coefﬁcient; ˇ, artery stiffne
T-cell count.
a There was statistically signiﬁcant association.4;1 8(5):496–500  499
present study, the participants had good treatment compli-
ance  (over 80%).
Jeong  et al.19 found that soluble receptor for advanced
glycation end-products (RAGE) may  have a protective effect
against  subclinical atherosclerosis by preventing inﬂamma-
tory  responses mediated by the activation of cell-surface
RAGE in HIV-infected patients receiving combined antiretro-
viral  therapy. However, other studies show opposing ﬁndings.
Jerico  et al.8 showed that HAART is a strong independent
predictive index of subclinical atherosclerosis. Seaberg et al.5
found that HAART could induce carotid artery stiffness in HIV-
infected  men  but not in HIV-infected women. As the present
research  has not studied the effects of gender on the cor-
relations  between carotid IMT and stiffness on HIV-infected
patients receiving HAART, more  research in this ﬁeld is neces-
sary  to clarify such effects.
This  study also reveals a statistically signiﬁcant corre-
lation between carotid artery stiffness and HIV infection
time, which indicates that HIV infection may  play a role
in  the development of atherosclerosis. No statistically sig-
niﬁcant  correlation between HIV infection time and carotid
artery  IMT was  observed. This ﬁnding may  be explained
by  the fact that the subjects showed mild disease signs
and  an inclusion criterion for the study was a normal IMT.
So  the correlate study outcome was  expected to be nega-
tive.  No statistically signiﬁcant correlations between stiffness,
IMT,  and CD4+ and CD8+ T-cell counts were observed, sim-
ilar  to ﬁndings by Seaberg et al.5 CD4+ and CD8+ T-cell
counts only reﬂect the immunological status upon blood
sampling, whereas carotid arterial IMT and stiffness may
be  affected by multiple factors operating over many  years.5
The artery stiffness of HIV-infected patients may  be induced
by  HIV itself, inﬂammation, and immunosuppression.20,21
Shrestha et al.22 also considered that the RYR3 gene may
be  correlated with carotid artery intima-media thicken-
ing  and induces atherosclerosis in HIV-infected patients on
HAART.
In  conclusion, the HAART regimens currently used in China
are  not related to carotid artery intima-media thickening or
stiffness  in HIV-infected patients with good treatment compli-
ance.  However, this study has several limitations. The sample
size  was  not very large and all participants had only mild HIV
disease.  We  did not study the effects of gender. Furthermore,
we  only analyzed the effects of NNRTI-containing HAART regi-
mens. Further follow up and research are necessary to reach
more  conclusive results.
 artery IMT  and stiffness (Pearson coefﬁcients/p-value).
 ˇ PWV
0.380/0.001a 0.417/0.000a
−0.096/0.476 −0.056/0.678
0.012/0.931 0.024/0.860
ss; PWV, pulse wave velocity; CD4+, CD4+ T-cell count; CD8+, CD8+
i s . 2 0
r
1
1
1
1
1
1
1
1
1
1
2
2500  b r a z j i n f e c t d 
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s
1. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the
risk  of death after HIV seroconversion compared with
mortality in the general population. JAMA. 2008;300:51–9.
2. Gallet B, Pulik M, Genet P, et al. Vascular complications
associated with use of HIV-protease inhibitors. Lancet.
1998;351:1958–9.
3. Sudano I, Speckler LE, Noll G, et al. Cardiovascular disease in
HIV  infection. Am Heart J. 2006;151:1147–55.
4.  Dubé MP, Lipshultz SE, Fichtenbaum CJ, et al. Effects of HIV
infection  and antiretroviral therapy on the heart and
vasculature. Circulation. 2008;118:e36–40.
5.  Seaberg EC, Benning L, Sharrett AR, et al. Association
between HIV infection and stiffness of the common carotid
artery.  Stroke. 2010;10:2163–70.
6. Boccara F. Cardiovascular complications and atherosclerotic
manifestations in the HIV-infected population: type,
incidence and associated risk factors. AIDS. 2008;22 Suppl.
3:s19–26.
7. Martin LS, Vandhuick O, Guillo P, et al. Premature
atherosclerosis in HIV positive patients and cumulated time
of  exposure to antiretroviral therapy (SHIVA study).
Atherosclerosis. 2006;185:361–7.
8.  Jerico C, Knobel H, Calvo N, et al. Subclinical carotid
atherosclerosis in HIV-infected patients: role of combination
antiretroviral therapy. Stroke. 2006;37:812–7.
9.  Andrade AC, Ladeia AM, Netto EM, et al. Cross-sectional study
of endothelial function in HIV-infected patients in Brazil.
AIDS  Res Hum Retroviruses. 2008;24:27–33.
0.  Torriani FJ, Komarow L, Parker RA, et al. Endothelial function
in  HIV-infected subjects before and after starting potent
antiretroviral therapy. J Am Coll Cardiol. 2008;52:569–76.
1. Ross AC, Rizk N, O’Riordan MA, et al. Relationship between
inﬂammatory markers, endothelial activation markers, and
2 1 4;1  8(5):496–500
carotid intima-media thickness in HIV-infected patients
receiving antiretroviral therapy. Clin Infect Dis.
2009;49:1119–27.
2. Baker JV, Henry WK, Patel P, et al. Progression of carotid
intima-media thickness in a contemporary human
immunodeﬁciency virus cohor. Clin Infect Dis. 2011;53:826–35.
3.  Currier JS, Kendall MA, Henry WK, et al. Progression of carotid
artery intima-media thickening in HIV-infected and
uninfected adults. AIDS. 2007;21:1137–45.
4.  Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV
infection and highly active antiretroviral therapy are
independent risk factors for early carotid atherosclerosis.
Atherosclerosis. 2008;196:720–6.
5.  Johnsen S, Dolan SE, Fitch KV, et al. Carotid intimal medial
thickness in HIV-infected women: effects of protease
inhibitor use, cardiac risk factors, and the metabolic
syndrome. J Clin Endocrinol Metab. 2006;91:4916–24.
6. Lundgren JD, Babiker A, EI-Sadr W,  et al. Inferior clinical
outcome of the CD4+ cell counts and HIV RNA levels during
follow-up.  J Infect Dis. 2008;197:1145–55.
7.  Farrugia PM, Lucariello R, Coppola JT. Human
immunodeﬁciency virus and atherosclerosis. Cardiol Rev.
2009;17:211–5.
8. van Leuven SI, Sankatsing RR, Vermeulen JN, et al.
Atherosclerotic vascular disease in HIV: it is not just
antiretroviral therapy that hurts the heart. Curr Opin HIV
AIDS.  2007;2:324–31.
9. Jeong SJ, Kim CO, Song YG, et al. Low plasma levels of the
soluble  receptor for advanced glycation end products in
HIV-infected patients with subclinical carotid atherosclerosis
receiving combined antiretroviral therapy. Atherosclerosis.
2011;219:778–83.
0. Baker JV, Lundgren JD. Cardiovascular implications from
untreated human immunodeﬁciency virus infection. Eur
Heart  J. 2011;32:945–51.
1. Anuurad E, Semrad A, Berglund L. Human immunodeﬁciency
virus and highly active antiretroviral therapy-associated
metabolic disorders and risk factors for cardiovascular
disease. Metab Syndr Relat Disord. 2009;7:401–10.
2.  Shrestha S, Irvin MR, Taylor KD, et al. A genome-wide
association study of carotid atherosclerosis in HIV-infected
men. AIDS. 2010;24:583–92.
